1675201-83-8
1675201-83-8
Chemical Structure
BMS-1
Synonym(s): PD-1/PD-L1 inhibitor 1
- CAS No.: 1675201-83-8
- Formula:C29H33NO5
- Molecular Weight:475.58
IUPAC Name: (S)-1-(2,6-dimethoxy-4-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)benzyl)piperidine-2-carboxylic acid
InChIKey: ZBOYJODMIAUJHH-SANMLTNESA-N
SMILES: O=C([C@H]1N(CC2=C(OC)C=C(OCC3=C(C)C(C4=CC=CC=C4)=CC=C3)C=C2OC)CCCC1)O
Biological Activity: BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BMS-1 | 99.53% | BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zhao Y, et al. Depression Promotes Hepatocellular Carcinoma Progression through a Glucocorticoids Mediated Up-Regulation of PD-1 Expression in Tumor infiltrating NK Cells. Carcinogenesis. 2019 Feb 4. [Content Brief]
- [2]. Li K, et al. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. J Drug Target. 2019 Mar;27(3):244-256. [Content Brief]
